COMPANY

Celestial Therapeutics Inc.

Keywords: vaccine mRNA oncology infectious disease rare disease infectious diseases rare diseases respiratory syncytial virus infectious disease

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $643K (SBIR Phase II 5R44AI177056-03, continuation, notice Jul 30, 2026). NIH RePORTER 5R44AI177056-03 (Jul 30, 2026)
Evidence (1 event)
- Jul 30, 2026 · NIH RePORTER 5R44AI177056-03
  Organization: CELESTIAL THERAPEUTICS INC.; City/State: IRVINE, CA; Project number: 5R44AI177056-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-30; FY total cost (award amount): 643140; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a dry powder inhalation product against Respiratory Syncytial Virus based on an endogenous anionic pulmonary surfactant lipid; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Jul 30, 2026 Grant Government grant — SBIR: $643,140 (annual award, as published), announced Jul 30, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Jul 30, 2025 Grant Government grant — SBIR: $1M (annual award, as published), announced Jul 30, 2025. Agency: NIH/NIAID. Source: government award database. source ↗

Last 2 years.

Jul 30, 2026 Government grant — SBIR: $643,140 (annual award, as published), announced Jul 30, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Jul 30, 2025 Government grant — SBIR: $1M (annual award, as published), announced Jul 30, 2025. Agency: NIH/NIAID. Source: government award database. source ↗